Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Assets Average (2021 - 2025)

Historic Assets Average for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $14.5 million.

  • InMed Pharmaceuticals' Assets Average rose 2985.14% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 2985.14%. This contributed to the annual value of $13.7 million for FY2025, which is 568.36% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Assets Average of $14.5 million as of Q3 2025, which was up 2985.14% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Assets Average ranged from a high of $18.4 million in Q4 2021 and a low of $8.9 million during Q1 2025
  • Its 5-year average for Assets Average is $13.7 million, with a median of $13.9 million in 2022.
  • Data for InMed Pharmaceuticals' Assets Average shows a peak YoY increase of 2985.14% (in 2025) and a maximum YoY decrease of 3785.55% (in 2025) over the last 5 years.
  • InMed Pharmaceuticals' Assets Average (Quarter) stood at $18.4 million in 2021, then fell by 14.18% to $15.8 million in 2022, then dropped by 16.92% to $13.1 million in 2023, then fell by 27.53% to $9.5 million in 2024, then soared by 52.58% to $14.5 million in 2025.
  • Its last three reported values are $14.5 million in Q3 2025, $12.4 million for Q2 2025, and $8.9 million during Q1 2025.